In addition, the content of the tau and α-synuclein in the cerebrospinal fluid is higher in patients with both PD and T2DM in relation to patients only with PD, and these markers are already upregulated in T2DM patients compared with healthy controls (Pagano et al., 2018), indicating a relationship between PD-pathology markers and T2DM. The gene discussed is MAPT; the disease is Parkinson disease.